X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The GINAKIT2 clinical trial is a phase I study of KUR-501, an autologous CAR-NKT cell product, targeting GD2 in patients with relapsed/refractory (R/R) high risk neuroblastoma conducted at Baylor College of Medicine (BCM) and Texas Children’s Hospital.
Lead Product(s): GINAKIT Cells,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: KUR-501
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Athenex
Deal Size: $185.0 million Upfront Cash: $70.0 million
Deal Type: Acquisition May 04, 2021
Details:
Interim data from GINAKIT2 and ANCHOR clinical studies provide evidence of efficacy for Kuur’s chimeric antigen receptor-natural killer T cell platform, KUR-501. First complete responses in patients treated with autologous and allogeneic engineered CAR-NKT cell therapies.
Lead Product(s): GINAKIT Cells,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: KUR-501
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Baylor College of Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2021
Details:
The interim results demonstrated that expressing the CAR with interlukin-15 (IL-15), a natural protein that supports NKT survival, enhanced the tumor-fighting capabilities and in vivo persistence of autologous NKT cells.
Lead Product(s): KUR-501,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: GINAKIT
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Baylor College of Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
Details:
KUR-502 is built on Kuur’s next-generation CAR-NKT platform, with novel engineering capabilities that harness and enhance the unique tumor-homing properties of NKT cells.
Lead Product(s): CAR-NKT Cell,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: KUR-502
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
The funding two phase 1 studies: GINAKIT 2 (autologous CAR-NKT cells in neuroblastoma) and ANCHOR (allogeneic CAR-NKT cells in CD19 malignancy).
Lead Product(s): CMD-501
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: IP Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
